UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 248

Sortiert nach

Prognostic factors for chemotherapy induced nausea and vomiting

European journal of pharmacology, 2014-01, Vol.722, p.192-196

Warr, David

2014

Volltextzugriff (PDF)

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.450-458

2015

Volltextzugriff (PDF)

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

Supportive care in cancer, 2014-06, Vol.22 (6), p.1685-1697

2014

Volltextzugriff (PDF)

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2822-2830

2005

Volltextzugriff (PDF)

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4112-4119

2003

Volltextzugriff (PDF)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Supportive care in cancer, 2011-06, Vol.19 (6), p.807-813

2011

Volltextzugriff (PDF)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.159-168

2018

Volltextzugriff (PDF)

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

Supportive care in cancer, 2016-05, Vol.24 (5), p.1941-1954

2016

Volltextzugriff (PDF)

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Supportive care in cancer, 2018-08, Vol.26 (8), p.2519-2549

2018

Volltextzugriff (PDF)

Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Supportive care in cancer, 2018-08, Vol.26 (8), p.2519

2018

Volltextzugriff (PDF)

Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5147-5152

2010

Volltextzugriff (PDF)

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Supportive care in cancer, 2017-01, Vol.25 (1), p.271-275

2017

Volltextzugriff (PDF)

Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice

Supportive care in cancer, 2018-03, Vol.26 (Suppl 1), p.29-33

Warr, David

2018

Volltextzugriff (PDF)

Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4175-4183

2003

Volltextzugriff (PDF)

Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3389-3394

2004

Volltextzugriff (PDF)

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Cancer, 2005-10, Vol.104 (7), p.1548-1555

2005

Volltextzugriff (PDF)

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Supportive care in cancer, 2011-03, Vol.19 (Suppl 1), p.43-47

2011

Volltextzugriff (PDF)

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Breast cancer research and treatment, 2008-03, Vol.108 (1), p.87-92

2008

Volltextzugriff (PDF)

Management of highly emetogenic chemotherapy

Current opinion in oncology, 2012-07, Vol.24 (4), p.371-375

Warr, David

2012

Volltextzugriff (PDF)

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

Supportive care in cancer, 2011-09, Vol.19 (9), p.1297-1302

2011

Volltextzugriff (PDF)

What Patients with Cancer Want to Know About Pain: A Qualitative Study

Journal of pain and symptom management, 2008-02, Vol.35 (2), p.177-187

2008

Volltextzugriff (PDF)

A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients

Journal of pain and symptom management, 2007-04, Vol.33 (4), p.365-371

2007

Volltextzugriff (PDF)

Supportive care in cancer—a MASCC perspective

Supportive care in cancer, 2020-08, Vol.28 (8), p.3467-3475

2020

Volltextzugriff (PDF)

Effect of postchemotherapy nausea and vomiting on health-related quality of life

Supportive care in cancer, 1997-07, Vol.5 (4), p.307-313

1997

Volltextzugriff (PDF)

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Supportive care in cancer, 2017-01, Vol.25 (1), p.277-288

2017

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(213)
Mit Volltextzugriff
(220)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(150)
Life Sciences & Biomedicine
(135)
Humans
(101)
Oncology
(63)
Female
(57)
Male
(47)
Biological And Medical Sciences
(42)
Middle Aged
(40)
Medical Sciences
(37)
Animals
(36)
Chemotherapy
(32)
Adult
(31)
Vomiting - Prevention & Control
(30)
Health Care Sciences & Services
(29)
Vomiting - Chemically Induced
(27)
Antiemetics - Therapeutic Use
(26)
Nausea
(25)
Rehabilitation
(25)
Antineoplastic Agents - Adverse Effects
(23)
Aged
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prognostic factors for chemotherapy induced nausea and vomiting

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice

Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Management of highly emetogenic chemotherapy

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)

What Patients with Cancer Want to Know About Pain: A Qualitative Study

A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients

Supportive care in cancer—a MASCC perspective

Effect of postchemotherapy nausea and vomiting on health-related quality of life

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Suchergebnisse filtern